TABLE 1.
Home spirometry measurements per subject over 52 weeks
Nintedanib | Placebo/nintedanib# | All subjects | |
Subjects | 116 | 230 | 346 |
Home spirometry measurements | |||
Mean±sd | 157±106 | 170±119 | 165±115 |
Minimum | 3 | 3 | 3 |
Median | 125 | 136 | 132 |
Maximum | 362 | 633 | 633 |
Data are presented as n, unless otherwise stated. #: subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.